# FDA 483 - Daniel Norman, M.D. - September 02, 2020

Source: https://www.keypedia.com/records/483/daniel-norman-md/d8d47ff9-b1a2-43f1-aa99-b9a2650b1975

> FDA 483 for Daniel Norman, M.D. on September 02, 2020. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Daniel Norman, M.D.
- Inspection Date: 2020-09-02
- Product Type: drugs
- Office Name: Division of Pharmaceutical Quality Operations IV
- Summary: An FDA inspection of Daniel Norman, M.D. in Santa Monica, CA, a clinical investigator, revealed a significant deviation from an investigational plan. The firm failed to conduct an investigation in accordance with the signed statement of investigator and protocol. Specifically, subjects were enrolled in a study while on prohibited concomitant medications, indicating a lack of adherence to study procedures.

## Related Documents

- [483 - 2023-10-17](https://www.keypedia.com/records/483/daniel-norman-md/5bafc539-7e39-4606-bd4b-e1b23a9c6bea)

## Related Officers

- [Kristin M. Abaonza](https://www.keypedia.com/people/kristin-m-abaonza/cf909da8-837d-4dfe-9ccc-288b24d7bba3)

Company: https://www.keypedia.com/companies/daniel-norman-md/bd34bdd0-4f58-4a86-9a6d-0cfc983e300c

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-iv/a2d2ff91-dc0f-433e-b91f-ca90ff8998b6